8-A12B 1 snbp20200824_8a12b.htm FORM 8-A12B snbp20200824_8a12b.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D
.C. 20549

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

SUN BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)

 

Delaware

 

87-0543922

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

712 Vista Blvd, Suite 305
Waconia, Minnesota

 

55387

(Address of principal executive offices)

 

(Zip Code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class to be so registered

 

Name of exchange on which each class is to be registered

Common Stock, par value $0.001 per share

 

The Nasdaq Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box: ☑ 

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box: ☐

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box: ☐

 

Securities Act registration statement file number to which this form relates: 333-239661

 

Securities to be registered pursuant to Section 12(g) of the Act: None

 

 

 

INFORMATION REQUIRED IN REGISTRATION STATEMENT

 

Item 1. Description of Registrant’s Securities to be Registered

 

The description of the common stock, par value $0.001 per share, of Sun BioPharma, Inc. (the “Company”), to be registered hereunder is incorporated by reference to the information set forth under the heading “Description of Capital Stock” contained in the Company’s registration statement on Form S-1 (File No. 333-239661) (the “Registration Statement”), originally filed with the Securities and Exchange Commission on July 2, 2020, as subsequently amended, and is hereby incorporated herein by reference. The description of the common stock included in any prospectus that constitutes a part of the Registration Statement and is subsequently filed by the Company pursuant to Section 424(b) of the Securities Act of 1933, as amended, shall also be deemed to be incorporated herein by reference.

 

Item 2. Exhibits

 

Pursuant to the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

SUN BIOPHARMA, INC.

     

Dated: August 24, 2020

By:

/s/ Susan Horvath

   

Susan Horvath
Vice President of Finance, Chief Financial Officer, Treasurer and Secretary